{
    "clinical_study": {
        "@rank": "13494", 
        "brief_summary": {
            "textblock": "To make stavudine (d4T) available to patients with advanced HIV disease for whom no\n      alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose\n      levels in a twice-daily regimen."
        }, 
        "brief_title": "A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs", 
        "completion_date": {
            "#text": "November 1991", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV positivity with CD4 count < 300 cells/mm3.\n\n          -  Intolerance to or failure on approved antiretroviral therapy.\n\n          -  Ability to provide informed consent (of parent or guardian if appropriate).\n\n        NOTE:\n\n          -  Incarcerated persons may be eligible to participate.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Grade 2 or worse disease-related peripheral neuropathy.\n\n          -  Unresolved drug-related peripheral neuropathy of any severity that is attributable to\n             other nucleoside analogs (AZT, ddC, ddI).\n\n          -  Malignancy likely to require systemic chemotherapy with myelosuppressive or\n             neurotoxic drugs in the first 3 months of stavudine treatment.\n\n          -  Pregnancy (physicians of pregnant patients may contact Bristol-Myers to determine\n             eligibility for stavudine therapy in another protocol).\n\n        Strongly discouraged:\n\n          -  AZT, ddI, ddC, and other antiretroviral agents."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002308", 
            "org_study_id": "116B", 
            "secondary_id": "AI455-900"
        }, 
        "intervention": {
            "intervention_name": "Stavudine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Stavudine", 
                "Anti-HIV Agents"
            ]
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Stavudine"
        ], 
        "lastchanged_date": "August 4, 2011", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Princeton", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "085434500"
                }, 
                "name": "Bristol - Myers Squibb Co"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized Blinded Evaluation of Two Doses of Stavudine (2',3'-Didehydro-2',3'-Dideoxythymidine; d4T) to Make Treatment Available to Severely Immunocompromised Patients With HIV Infection Who Have Failed or Are Intolerant of Alternative Antiretroviral Therapy", 
        "overall_official": {
            "affiliation": ".", 
            "last_name": ". .", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002308"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2011"
    }, 
    "geocoordinates": {
        "Bristol - Myers Squibb Co": "40.366 -74.679"
    }
}